Literature DB >> 25986758

Kidney cancer: SWITCHing inconsequential.

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25986758     DOI： 10.1038/nrurol.2015.116

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Authors:  Christian Eichelberg; Walter L Vervenne; Maria De Santis; Ludwig Fischer von Weikersthal; Peter J Goebell; Christian Lerchenmüller; Uwe Zimmermann; Monique M E M Bos; Werner Freier; Silke Schirrmacher-Memmel; Michael Staehler; Sascha Pahernik; Maartje Los; Marcus Schenck; Anne Flörcken; Cornelis van Arkel; Kirsten Hauswald; Martin Indorf; Dana Gottstein; Maurice S Michel
Journal:  Eur Urol       Date:  2015-05-04       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.